• Regulatory NewsRegulatory News

    Researchers Call on FDA to Rethink Guidance Allowing Use of Surrogate Outcomes

    The US Food and Drug Administration (FDA) needs to reconsider its use of surrogate outcomes in some guidance documents on developing treatments for infectious diseases, researchers from Harvard and George Washington University School of Medicine wrote in a review published Tuesday in JAMA Internal Medicine . The review evaluated 22 FDA guidance documents, which included recommendations for pivotal clinical trials in 27 disease indications. For six indications (22%), on...
  • Regulatory NewsRegulatory News

    WHO Seeks to Expand Access to Insulin With Prequalification Program

    As only about half of the 65 million people worldwide with Type 2 diabetes who need insulin can access it, the World Health Organization (WHO) on Wednesday announced the creation of the first prequalification program for insulin manufacturers. The pilot prequalification program seeks to expand the pool of quality insulin products via an evaluation to ensure their quality, safety and efficacy. WHO said the program is limited to insulin products either approved by a st...
  • Regulatory NewsRegulatory News

    FDA’s Project Orbis May Expand to Singapore and Switzerland

    The US Food and Drug Administration (FDA) may expand a pilot project that allows for simultaneous drug approval decisions from US, Canadian and Australian regulators to include Singapore and Switzerland, Richard Pazdur, director of FDA’s Oncology Center of Excellence, said Tuesday at the Friends of Cancer Research's annual meeting in Washington, DC. If Singapore and Switzerland are added, Pazdur said following visits to both countries, it would further collaborations bet...
  • Regulatory NewsRegulatory News

    EC Offers Further Clarity on Clinical Trial Regulation

    The European Commission (EC) recently updated guidance on the incoming clinical trials regulation, with new questions and answers (Q&As) on requests for information (RFIs), how assessment reports will be made public and the sponsor’s responsibilities regarding changes to a clinical trial that are not substantial modifications but are relevant for supervising the trial. On the question (number 2.7) of the management of a request for information during the initial assessm...
  • Regulatory NewsRegulatory News

    FDA Warns Mylan’s Indian API Facility Over Contamination Concerns

    The US Food and Drug Administration (FDA) on Tuesday released a warning letter sent last week to Mylan’s active pharmaceutical ingredient (API) manufacturing site in Andhra Pradesh, India, highlighting “contamination at levels above the limit” for some API batches. FDA’s inspection of the site in May and June uncovered, “Multiple contract manufacturers supplied solvents that were contaminated with [redacted], but your firm lacked documentation of which tanks were used t...
  • Regulatory NewsRegulatory News

    France to Maintain Fast Track Schemes for Clinical Trials

    As the new EU clinical trial regulation is expected to take effect next spring, France’s drug regulator, Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), said it will maintain two fast tracks to speed clinical trials for new and already known medicinal products. The two fast track processes, which were established last year and then extended to advanced therapy medicinal products (ATMPs) in February, allow for innovative drug trial applicati...
  • Regulatory NewsRegulatory News

    Regenxbio Sues FDA Over Unexplained Clinical Trial Hold

    Biotech company Regenexbio sued the US Food and Drug Administration (FDA) last week for failing to provide an explanation for placing a hold on a clinical trial for an experimental gene therapy to treat wet age-related macular degeneration. FDA’s decision effectively halted the development of the potential one-time subretinal treatment without a clear basis, the complaint said. “By failing to provide advance notice of, or any reasoned basis for, the clinical hold, FD...
  • Regulatory NewsRegulatory News

    Orphan Drug Recall Leaves Patients in the Lurch

    When Brenda Shelton, a hair stylist in Las Vegas, logged into a private Facebook group in September, she did not expect to find out about a recall of an injectable drug she takes to control her hypoparathyroidism, a rare disorder with potentially deadly complications. And since Takeda’s Natpara (parathyroid hormone) injection is the only effective treatment for Shelton, she knew when she received an official Takeda recall letter via UPS four days later that difficulties...
  • Regulatory NewsRegulatory News

    WHO Commends Russian Response to Proposed Heritable Human Genome Editing

    Following the birth of the world’s first genome-edited babies in November 2018, the World Health Organization’s (WHO) Expert Advisory Committee on Human Genome Editing was established a month later to further understand and regulate human genome editing in both somatic cells and cells of the germline, including early embryos. Since its establishment, Denis Rebrikov, chief geneticist at Russia’s largest government-run in vitro fertilization clinic, sought to genetically ...
  • Regulatory NewsRegulatory News

    ICH Survey Shows Wide Adoption of Guidelines Among Regulators, Industry

    A recently released survey from the International Council on Harmonisation (ICH) shows pharmaceutical regulators and companies around the world are adopting and adhering to the council’s guidelines related to quality, safety and efficacy. The survey of 32 pharmaceutical companies provided responses on 15 regulatory authorities, which included the founding ICH members: the European Medicines Agency, the US Food and Drug Administration, Japan’s MHLW/PMDA, Health Canada an...
  • Regulatory NewsRegulatory News

    FDA to Revoke Orphan Designation for Opioid Addiction Drug Sublocade

    The US Food and Drug Administration (FDA) said Thursday that it has decided to revoke the orphan designation granted to Indivior’s opioid use disorder (OUD) treatment Sublocade (buprenorphine extended-release injection). Approved as a sublingual tablet in 2002 and known as Subutex (buprenorphine), the drug received orphan designation and seven years of exclusivity thorough 2009. In 2017, FDA approved Indivior’s extended release injection of buprenorphine, known as Sublo...
  • Regulatory NewsRegulatory News

    EC Extends Deadline for Experts to Apply for MDR/IVDR Panels

    The European Commission (EC) said Thursday that it has extended the deadline by almost two weeks for experts to apply to be a part of panels that will evaluate high-risk medical devices and in vitro diagnostics (IVDs) under the incoming Medical Devices Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR). The new deadline is 24 November. As first discussed in September, panel experts are expected to be objective (EC says they must have no financial or other in...